Product Description
AstraZeneca was developing azd-3161, an injectable NaV1.7 blocker, for the treatment of mechanical pain sensitivity and axon reflex flare in normal and ultraviolet C irradiated skin (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01240148)
Mechanisms of Action: NaV1.7 Blocker
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: Europe
Company CEO: Pascal Soriot
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Neuropathic Pain|Nociceptive Pain|Neuralgia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01240148 |
D3780C00005 | P1 |
Completed |
Neuralgia|Nociceptive Pain|Neuropathic Pain |
2011-03-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|